Drug intelligence / Profile preview

technetium-99m DPD

Development stage
Unknown
Lead developer
Curium
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Technetium-99m DPD (technetium-99m dicarboxypropane diphosphonate) is a small molecule radiopharmaceutical used for diagnostic imaging. It consists of the radioactive isotope technetium-99m complexed with the diphosphonate ligand 3,3-diphosphono-1,2-propanodicarboxylic acid. The agent exhibits high affinity for hydroxyapatite crystals in bone, making it a standard tool for bone scintigraphy to detect metastases, fractures, and inflammatory bone diseases. Additionally, it has become a critical diagnostic tool for transthyretin cardiac amyloidosis (ATTR), as it selectively accumulates in myocardial amyloid deposits. Following intravenous administration, the gamma radiation emitted by technetium-99m is captured using Single Photon Emission Computed Tomography (SPECT) imaging to provide high-resolution anatomical and functional data.

Brand names
Teceos
Other names
technetium-99m dicarboxypropane diphosphonatetechnetium99m dicarboxypropane diphosphonatetechnetium 99m dicarboxypropane diphosphonatetechnetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid99mTc-3,3-diphosphono-1,2-propane dicarboxylic acid tetrasodium salt
02

Targets

TTR amyloid fibril (Transthyretin amyloid fibril)AL (Amyloid light-chain protein)

Beyond the preview

Go deeper on technetium-99m DPD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium-99m DPD.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call